Tempus AI surges on q2 profit, FDA wins—but risks loom

The gist
Tempus AI just posted its first-ever profit and a massive revenue leap, but looming reimbursement delays and hefty AI costs threaten to rain on its cancer-cure parade.
What to know
- Q2 2026 revenue jumped 21.6% to $382.5M, with Tempus notching its first GAAP net income profit of $5.6M—fueled by its Personalis acquisition.
- FDA cleared Tempus ECG-PH, its third cardiovascular AI tool, while strategic partnerships like CellCarta are embedding Tempus Hub deeper into oncology workflows.
- Despite boosting 2026 guidance and eyeing $85M+ in new pricing-related revenue, Tempus faces a $254.4M net loss and a 16.4% shareholder drop over the past year.
Strategic Moves, Uncertain Payoff
Tempus AI’s aggressive expansion through oncology partnerships and new diagnostic approvals promises major revenue gains, but costly infrastructure investments and regulatory hurdles threaten to slow its path to sustained profitability.
Tempus AI's strategic inclusion in CellCarta’s CDx Commercialization Lab Network marks a pivotal step in embedding its Tempus Hub platform into oncology workflows, streamlining provider test ordering and result delivery. This collaboration not only accelerates platform adoption but also underpins the company's raised 2026 revenue guidance, supporting a robust projection of 20.8% annual revenue growth to $2.4 billion by 2029. However, despite this momentum, investors remain cautious due to potential reimbursement delays and the high costs associated with scaling AI infrastructure, which could temper profitability and delay commercialization timelines.
The recent FDA approval for Tempus AI's tumor-only xT companion diagnostic ushers in a transition to unified ADLT pricing, expected to boost the average selling price by approximately $200 per test starting in 2027. This pricing shift could add around $85 million in annual revenues relative to the $289.3 million reported in Q2 2026, with further upside anticipated from the pending FDA approval of the xF liquid biopsy assay in late 2027, potentially adding an incremental $550 to the average selling price. While these reimbursement gains could collectively contribute roughly $400 million in revenue uplift by 2028, their full realization hinges on successful regulatory approvals and expanded payer coverage, with delays posing risks to near-term revenue and margin expansion.
Tempus AI demonstrated strong financial performance in Q2 2026, reporting $382.5 million in revenue—a 21.6% year-over-year increase—and raising full-year guidance to approximately $1.6 billion, signaling about 25% growth. The company also posted its first GAAP net income profit of $5.6 million for the quarter, primarily driven by paper gains from its investment in Personalis, which Tempus is in the process of acquiring. This acquisition, alongside the CellCarta partnership, highlights a strategic push to expand market presence and enhance valuation, though ongoing net losses of $254.4 million and a negative one-year shareholder return of 16.4% underscore persistent financial challenges that temper the otherwise optimistic outlook.
AI Transforms Heart Disease Detection
Tempus ECG-PH’s FDA clearance signals a leap forward in non-invasive cardiac diagnostics, enabling earlier pulmonary hypertension detection for at-risk patients and positioning Tempus at the forefront of AI-driven cardiovascular care.
Tempus AI’s FDA clearance of its third cardiovascular algorithm, the Tempus ECG-PH software, marks a pivotal advancement in AI-driven cardiac diagnostics by enabling non-invasive detection of pulmonary hypertension through standard 12-lead ECGs. Building on prior clearances for atrial fibrillation and low ejection fraction detection, this latest tool expands Tempus’ portfolio and underscores the company’s commitment to transforming routine ECGs into powerful screening instruments for complex cardiovascular diseases.
Targeting symptomatic patients aged 40 and older, Tempus ECG-PH provides clinicians with a binary output indicating elevated mean pulmonary artery pressure, a key marker of pulmonary hypertension. This point-of-care triage tool complements existing diagnostic pathways by analyzing resting, non-ambulatory ECGs and facilitating earlier identification of a condition historically underdiagnosed due to non-specific symptoms and reliance on invasive tests, as noted by Dr. Brandon Fornwalt, Senior VP of Cardiology at Tempus.
